Double-blind placebo-controlled study of mesalamine in post-infective irritable bowel syndrome--a pilot study.

Post-infective irritable bowel syndrome (PI-IBS) is characterized by continuing symptoms of irritable bowel syndrome, typically diarrhea-predominant, following an episode of acute gastroenteritis. There is often an increase in sub-epithelial inflammatory and neuroendocrine cells on colonic mucosal biopsy. Mesalamine is an anti-inflammatory agent, effective in the treatment of inflammatory bowel disease. The goal of this study was to compare mesalamine to placebo on symptoms and quality-of-life (QOL) in PI-IBS.
Twenty patients who developed diarrhea-predominant IBS after gastroenteritis were randomized to receive mesalamine (Asacol®) 1.6 gm b.i.d. or placebo for 12 weeks in a double-blind placebo-controlled study. QOL was assessed using the IBS-QOL questionnaire. Stool frequency, stool consistency, urgency, severity of abdominal pain, severity of bloating, and global-improvement scale were recorded in daily diaries for 7 days at baseline and every 4 weeks. Data were analyzed by comparing the change from baseline to last follow-up.
One patient withdrew after randomization; data were incomplete in two patients. Thus, data were analyzed from 17 patients (11 men and 6 women, median age: 27 years, range 22-45 years). Mesalamine was not associated with significant improvement in global symptoms, abdominal pain, bloating, stool urgency, frequency, or consistency (all p ≥ 0.11) or QOL (p ≥ 0.16).
There was no significant improvement in global symptoms or overall QOL with mesalamine in patients with PI-IBS.
AuthorsAshok K Tuteja, John C Fang, Manal Al-Suqi, Gregory J Stoddard, Devon C Hale
JournalScandinavian journal of gastroenterology (Scand J Gastroenterol) Vol. 47 Issue 10 Pg. 1159-64 (Oct 2012) ISSN: 1502-7708 [Electronic] England
PMID22783919 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Anti-Inflammatory Agents, Non-Steroidal
  • Mesalamine
  • Abdominal Pain (etiology, physiopathology)
  • Acute Disease
  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal (administration & dosage)
  • Biopsy
  • Diarrhea (etiology, physiopathology)
  • Double-Blind Method
  • Female
  • Gastroenteritis (complications)
  • Humans
  • Intestinal Mucosa (pathology)
  • Irritable Bowel Syndrome (drug therapy, etiology, pathology, physiopathology, psychology)
  • Male
  • Mesalamine (administration & dosage)
  • Pain Measurement
  • Pilot Projects
  • Quality of Life
  • Severity of Illness Index
  • Surveys and Questionnaires
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: